血液细胞重编程为诱导性多能干细胞的研究进展

张玥 武玢 宮甜甜 雷蕾 单智焱*

doi:10.16098/j.issn.0529-1356.2015.06.022

解剖学报 ›› 2015, Vol. 46 ›› Issue (6) : 852-856. DOI: 10.16098/j.issn.0529-1356.2015.06.022

综述

血液细胞重编程为诱导性多能干细胞的研究进展

张玥武玢宮甜甜雷蕾单智焱*

作者信息 +

Progress of blood cells reprogramming to induced pluripotent stem cells

ZHANG Yue WU Bin GONG Tian-tian LEI Lei SHAN Zhi-yan*

Author information +

文章历史 +

摘要

诱导性多能干细胞（iPSCs)技术能够将已分化的体细胞反转为多能细胞，因其不存在伦理、排斥等问题，在再生医学领域具有广阔的应用前景。尽管已经建立了来源于多种体细胞的诱导性多能干细胞，但是能实际应用于临床、取材便利、诱导安全的供体来源仍然具有局限性。我们从血液细胞作为供体细胞进行重编程的特点、优势及应用等方面进行了综述。

Abstract

Induced pluripotent stem cells (iPSCs) technology can revert differentiated cells to pluripotent cells and avoid the limitation such as ethics, immunerejection. It has broad applications in the field of regenerative medicine. Although induced pluripotent stem cells have already set up for all sorts of donor cells, the application in clinical facilities and induction of donor origin still has various limitations. In this review, we discuss the characteristics, advantages and applications of utilizing blood cells as donor cells for reprogramming, providing a theoretical basis for the ultimate applications of induced pluripotent stem cells in clinical studies.

导出引用

张玥武玢宮甜甜雷蕾单智焱*. 血液细胞重编程为诱导性多能干细胞的研究进展[J]. 解剖学报. 2015, 46(6): 852-856 https://doi.org/10.16098/j.issn.0529-1356.2015.06.022

ZHANG Yue WU Bin GONG Tian-tian LEI Lei SHAN Zhi-yan*. Progress of blood cells reprogramming to induced pluripotent stem cells[J]. Acta Anatomica Sinica. 2015, 46(6): 852-856 https://doi.org/10.16098/j.issn.0529-1356.2015.06.022

参考文献

［1］Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors［J］. Cell, 2006, 126(4): 663-676.
［2］Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors［J］. Cell, 2007, 131(5): 861-872.
［3］Yu J, Vodyanik MA, SmugaOtto K, et al. Induced pluripotent stem cell Lines derived from human somatic cells［J］. Science, 2007,318(5858): 1917-1920.
［4］Di Stefano B, Graf T. Very rapid and efficient generation of induced pluripotent stem cells from mouse Pre-B cells［J］. Methods Mol Biol, 2014 ［Epub ahead of print］.
［5］Merkl C, Saalfrank A, Riesen N, et al. Efficient generation of rat induced pluripotent stem cells using a non-viral inducible vector［J］. PLoS One, 2013, 8(1): e55170.
［6］Shimozawa N. Cynomolgus monkey induced pluripotent stem cells generated by using allogeneic genes［J］. Methods Mol Biol, 2014［Epub ahead of print］.
［7］Fujie Y, Fusaki N, Katayama T, et al. New type of sendai virus vector provides transgenefree iPS cells derived from chimpanzee blood［J］. PLoS One, 2014, 9(12): e113052.［8］Li X, Shan ZY, Wu YS, et al. Generation of neural progenitors from induced Bama miniature pig pluripotent cells［J］. Reproduction, 2014, 147(1): 65-72.
［9］Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells［J］. Cell, 2010, 143(4): 527-539.
［10］Ikehata H, Masuda T, Sakata H, et al. Analysis of mutation spectra in UVB-exposed mouse skin epidermis and dermis: frequent occurrence of C→T transition at methylated CpG-associated dipyrimidine sites［J］. Environ Mol Mutagen, 2003, 41(4): 280-292.
［11］Yamanaka S. Patient-specific pluripotent stem cells become even more accessible［J］. Cell Stem Cell, 2010, 7(1): 1-2.
［12］Loh YH, Hartung O, Li H, et al. Reprogramming of T cells from human peripheral blood［J］. Cell Stem Cell, 2010, 7(1): 15-19.
［13］Staerk J, Dawlaty MM, Gao Q, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells［J］. Cell Stem Cell, 2010, 7(1): 20-24.
［14］Chou BK, Mali P, Huang X, et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures［J］. Cell Res, 2011, 21(3): 518-529.
［15］Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells［J］. Nature, 2010, 467(7313): 285-290.
［16］Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency［J］. Cell, 2008, 133(2): 250-264.
［17］Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53p21 pathway［J］. Nature, 2009, 460(7259): 1132-1135.
［18］Eminli S, Foudi A, Stadtfeld M, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells［J］. Nat Genet, 2009, 41(9): 968-976.
［19］Di Stefano B, Sardina JL, van Oevelen C, et al. C/EBPalpha poises B cells for rapid reprogramming into induced pluripotent stem cells［J］. Nature, 2014, 506(7487): 235-239.［20］Hubbard JJ, Sullivan SK, Mills JA, et al. Efficient iPS cell generation from blood using episomes and HDAC inhibitors［J］. J Vis Exp, 2014,(92): e52009.
［21］Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells［J］. Blood, 2011, 117(14):109-119. 
［22］Su RJ, Neises A, Zhang XB,et al. Generation of iPS cells from human peripheral blood mononuclear cells using episomal vectors［J］. Methods Mol Biol, 2014［Epub ahead of print］.
［23］Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells［J］. Cell Stem Cell, 2010, 7(1): 11-14.
［24］Merling RK, Sweeney CL, Choi U, et al.Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells［J］.Blood, 2013,121(14):e98-107.
［25］Zhou H, Martinez H, Sun B, et al. Rapid and efficient generation of transgene-free iPSC from a small volume of cryopreserved blood［J］. Stem Cell Rev, 2015, 11(4): 652-665.［26］Ye Z, Zhan H, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders［J］. Blood, 2009, 114(27): 5473-5480.
［27］Hiramoto T, Ebihara Y, Mizoguchi Y, et al. Wnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia patient-derived pluripotent stem cells［J］. Proc Natl Acad Sci USA, 2013, 110(8): 3023-3028.